|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 74.00 GBX | 0.00% |
|
+2.07% | +0.68% |
| 11-04 | Arecor Gains US, European Patents for Insulin Product Formulations, Intellectual Property | MT |
| 11-04 | Arecor Therapeutics plc Enhances Ip Coverage for AT278 and Oral Delivery Technology | CI |
| Capitalization | 27.94M 37.23M 32M 29.98M 51.61M 3.35B 56.13M 351M 135M 1.58B 140M 137M 5.79B | P/E ratio 2025 * |
-
| P/E ratio 2026 * | - |
|---|---|---|---|---|---|
| Enterprise value | 23.5M 31.3M 26.91M 25.21M 43.4M 2.82B 47.2M 295M 114M 1.33B 117M 115M 4.87B | EV / Sales 2025 * |
7.35x | EV / Sales 2026 * | 22.3x |
| Free-Float |
58.34% | Yield 2025 * |
-
| Yield 2026 * | - |
More valuation ratios
* Estimated data
More news
Last Transcript: Arecor Therapeutics plc
More press releases
| 1 week | +2.07% | ||
| Current month | +2.07% | ||
| 1 month | +2.07% | ||
| 3 months | +4.96% | ||
| 6 months | +70.11% | ||
| Current year | +0.68% |
| 1 week | 70 |  | 78 |
| 1 month | 69.05 | | 78 |
| Current year | 35.4 | | 100 |
| 1 year | 35.4 | | 100 |
| 3 years | 35.4 | | 322 |
| 5 years | 35.4 | | 472 |
| 10 years | 35.4 | | 472 |
| Manager | Title | Age | Since |
|---|---|---|---|
Sarah Howell
CEO | Chief Executive Officer | 50 | 12/04/2021 |
David J. Ellam
DFI | Director of Finance/CFO | - | 17/11/2024 |
Jan Jezek
CTO | Chief Tech/Sci/R&D Officer | - | 31/07/2007 |
| Director | Title | Age | Since |
|---|---|---|---|
Sarah Howell
BRD | Director/Board Member | 50 | 12/04/2021 |
Mohammad Fazeli
BRD | Director/Board Member | 60 | 31/08/2017 |
Andrew Richards
CHM | Chairman | 65 | 12/04/2021 |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 0.00% | +2.07% | -3.27% | -70.40% | 37.23M | |
| -0.95% | -1.24% | +4.02% | +12.98% | 47.37B | |
| +0.41% | -1.81% | +11.46% | +7.61% | 38.46B | |
| -2.56% | -5.20% | +57.04% | +72.14% | 35.73B | |
| +0.38% | -1.24% | +11.14% | +21.03% | 27.23B | |
| +0.61% | -7.48% | +56.37% | +169.06% | 15.44B | |
| +1.48% | +2.42% | +65.68% | +225.06% | 15.4B | |
| +0.05% | +0.47% | -14.53% | -7.21% | 14.19B | |
| +0.43% | -1.63% | +51.98% | - | 13.64B | |
| -0.16% | -1.27% | +114.33% | +114.78% | 13.23B | |
| Average | -0.03% | -1.50% | +35.42% | +60.56% | 22.07B | |
| Weighted average by Cap. | -0.33% | -2.09% | +31.12% | +55.76% |
| 2025 * | 2026 * | |
|---|---|---|
| Net sales | 3.2M 4.26M 3.66M 3.43M 5.91M 383M 6.42M 40.13M 15.49M 181M 15.99M 15.65M 662M | 1.22M 1.62M 1.39M 1.3M 2.24M 146M 2.44M 15.25M 5.89M 68.81M 6.08M 5.95M 252M |
| Net income | - | - |
| Net Debt | -4.44M -5.92M -5.09M -4.77M -8.21M -533M -8.93M -55.77M -21.53M -252M -22.22M -21.75M -920M | -855K -1.14M -980K -918K -1.58M -103M -1.72M -10.73M -4.14M -48.44M -4.28M -4.19M -177M |
More financial data
* Estimated data
Employees
44
Calendar
| Date | Price | Change | Volume |
|---|---|---|---|
| 05/12/25 | 74.00 p | 0.00% | 11,876 |
| 04/12/25 | 74.00 p | 0.00% | 10,979 |
| 03/12/25 | 74.00 p | +2.07% | 16,988 |
| 02/12/25 | 72.50 p | 0.00% | 15,468 |
| 01/12/25 | 72.50 p | 0.00% | 6,956 |
Delayed Quote London S.E., December 05, 2025 at 04:35 pm
More quotes
Sell
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
0.7400GBP
Average target price
2.755GBP
Spread / Average Target
+272.30%
Annual profits - Rate of surprise
- Stock Market
- Equities
- AREC Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition